Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

755.00 +6.99 (+0.93%)
Official Closing Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
This Is What Whales Are Betting On Eli Lilly and Co
Via Benzinga
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
Hedge Fund Legend Druckenmiller Shares His Top Secrets For 30% Returns
Legendary hedge fund manager Stanley Druckenmiller made right bets at the right time. He came to fame for earning Soros $10B overnight. Successful hedge fund, Duquesne Capital, boasts $10B fortune. 
Via Benzinga
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $2,200 Today
Via Benzinga
This Is What Whales Are Betting On Eli Lilly and Co
Via Benzinga
Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
What About Eli Lilly's Drug For Early Alzheimer's? FDA Panel To Discuss Next Month
FDA's advisory committee meeting on June 10, 2024, discussing Eli Lilly's donanemab for early Alzheimer's. 
Via Benzinga
Exposures Product Safety
Sigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Sigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral &amp; Bacterial Infections"
SAN DIEGO, CA - (NewMediaWire) - May 07, 2024 - Sigyn Therapeutics, Inc. (“Sigyn Therapeutics”, “Sigyn” or the “Company”) (OTCQB: “SIGY”), a development-stage medical technology company, announced... 
Via TheNewswire.com
Exposures COVID-19
Why Eli Lilly Stock Jumped by 4% Today
The company's payout is far from the only reason investors like the stock these days, but it certainly helps. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs 
Via MarketBeat
2 Top Stocks That Could Make You Richer in 2024
Here are a couple of great ideas on where to invest your money today. 
Via The Motley Fool
3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years
These stocks have rock-solid businesses and they have impressive track records for paying dividends. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in May
These great stocks are great picks for investors as spring winds down. 
Via The Motley Fool
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro. 
Via The Motley Fool
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
The anti-obesity medication stock is way up, and there could be more fuel in the tank. 
Via The Motley Fool
Why Amgen Stock Zoomed Nearly 12% Higher Today
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop. 
Via The Motley Fool
3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030
These under-the-radar stocks have the potential to reach a $1 trillion valuation by 2030 as they gain momentum in their respective industries. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Wage Growth Slows – Stock Market Celebrates, Five Real Reasons Apple Is Running Up
To gain an edge, this is what you need to know today. 
Via Benzinga
1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $892. Is It a Buy?
The company seems to be going from strength to strength lately. 
Via The Motley Fool
Weigh Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
Reduced prices on Wegovy and Mounjaro at British pharmacies amid growing competition. Simple Online Pharmacy slashes Mounjaro starter doses to £149 from £179, catering to high demand. 
Via Benzinga
3 Stocks Gunning for Trillion-Dollar Status: The Players to Own Now
These three stocks closing in on trillion-dollar valuations are ready to stand shoulder-to-shoulder with other industry giants. 
Via InvestorPlace
3 Staples Stocks to Cushion Lower Consumer Sentiment
Three stocks in the consumer staples sector could come to save investor portfolios from potential underperformance following sentiment contractions 
Via MarketBeat
Topics Economy
Exposures Economy
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly. 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.